Abstract
The carbonic anhydrases (CAs, EC 4.2.1.1) are zinc containing metalloenzymes which catalyse efficiently the reversible hydration of carbon dioxide to bicarbonate with discharge of a proton, playing important physiological and physiopathological functions. To date, 16 different carbonic anhydrase isoforms have been described in higher vertebrates, including humans, and some of them have been considered as important targets for inhibitors with therapeutic applications. The catalytic and structural role of zinc in these enzyme are understood in great detail, and this provided molecular basis for the design of potent inhibitors, some of which possessing important clinical applications mainly as topically acting anti-glaucoma drugs, anticancer or antiobesity agents. The metal binding function is a critically important factor in the development of isozyme-specific and organ-selective inhibitors. Discovery of compounds that possess zinc binding function different from that of the classical one (sulfonamide type) is in constant progress and can offer opportunities for developing novel pharmacological agents. In the present review we will discuss the different zinc binding function reported in the literature up to now in the design of carbonic anhydrase inhibitors.
Keywords: Zinc binding functions, sulfamate, tumors, classical cytosolic isoforms, Urea
Current Topics in Medicinal Chemistry
Title: Metal Binding Functions in the Design of Carbonic Anhydrase Inhibitors
Volume: 7 Issue: 9
Author(s): Jean-Yves Winum, Andrea Scozzafava, Jean-Louis Montero and Claudiu T. Supuran
Affiliation:
Keywords: Zinc binding functions, sulfamate, tumors, classical cytosolic isoforms, Urea
Abstract: The carbonic anhydrases (CAs, EC 4.2.1.1) are zinc containing metalloenzymes which catalyse efficiently the reversible hydration of carbon dioxide to bicarbonate with discharge of a proton, playing important physiological and physiopathological functions. To date, 16 different carbonic anhydrase isoforms have been described in higher vertebrates, including humans, and some of them have been considered as important targets for inhibitors with therapeutic applications. The catalytic and structural role of zinc in these enzyme are understood in great detail, and this provided molecular basis for the design of potent inhibitors, some of which possessing important clinical applications mainly as topically acting anti-glaucoma drugs, anticancer or antiobesity agents. The metal binding function is a critically important factor in the development of isozyme-specific and organ-selective inhibitors. Discovery of compounds that possess zinc binding function different from that of the classical one (sulfonamide type) is in constant progress and can offer opportunities for developing novel pharmacological agents. In the present review we will discuss the different zinc binding function reported in the literature up to now in the design of carbonic anhydrase inhibitors.
Export Options
About this article
Cite this article as:
Winum Jean-Yves, Scozzafava Andrea, Montero Jean-Louis and Supuran T. Claudiu, Metal Binding Functions in the Design of Carbonic Anhydrase Inhibitors, Current Topics in Medicinal Chemistry 2007; 7 (9) . https://dx.doi.org/10.2174/156802607780636771
DOI https://dx.doi.org/10.2174/156802607780636771 |
Print ISSN 1568-0266 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4294 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Recent Advances in the Synthesis of Heterocycles via Gold-catalyzed Cascade Reactions: A Review
Current Organic Chemistry Molecular Damage in Glaucoma: from Anterior to Posterior Eye Segment. The MicroRNA Role
MicroRNA Dystroglycan, A Multifunctional Adaptor Protein for Signal Transduction and A Potential Therapeutic Target
Current Signal Transduction Therapy Programming Apoptosis and Autophagy with Novel Approaches for Diabetes Mellitus
Current Neurovascular Research Histone Deacetylase Inhibitors Target Diabetes via Chromatin Remodeling or as Chemical Chaperones?
Current Diabetes Reviews Signal Transduction Pathways and Transcription Factors as Therapeutic Targets in Inflammatory Disease: Towards Innovative Antirheumatic Therapy
Current Pharmaceutical Design Role of Chitosan Biomaterials in Drug Delivery Systems: A Patent Perspective
Recent Patents on Materials Science Immune Checkpoint Inhibitors for Non-small-cell Lung Cancer: Does that Represent a ‘New Frontier’?
Anti-Cancer Agents in Medicinal Chemistry Understanding Tumor-Antigen Presentation in the New Era of Cancer Immunotherapy
Current Pharmaceutical Design Antimicrobial Peptides as a Strategy to Combat Fungal Biofilms
Current Topics in Medicinal Chemistry Forensic DNA Phenotyping in Criminal Investigations and Criminal Courts: Assessing and Mitigating the Dilemmas Inherent in the Science
Recent Advances in DNA & Gene Sequences (Discontinued) Therapeutic Window, a Critical Developmental Stage for Stem Cell Therapies
Current Stem Cell Research & Therapy Identification of Immunogenic MHC Class II Tyrosinase-Derived Peptides Using HLA-DR1 and HLA-DR4 Transgenic Mice
Protein & Peptide Letters Drug Targeting Approaches and Use of Drug Delivery Systems in Management of Cancer
Current Pharmaceutical Design HIV-1 Vectors: Fulfillment of Expectations, Further Advancements, and Still A Way To Go
Current HIV Research Implantable Microfluidic Device: An Epoch of Technology
Current Pharmaceutical Design XSTING, Software for Evaluation of Radiotherapy Planning Performed Using EGSnrcMP Codes
Current Medical Imaging Nanotechnology in Therapeutics – Current Technologies and Applications
Current Nanoscience A Key Role for Connexin Hemichannels in Spreading Ischemic Brain Injury
Current Drug Targets Neurochemistry Changes Associated with Mutations in Familial Parkinsons Disease
Current Medicinal Chemistry